Guidance for UK Practitioners

Guidance from the National Institute for Health and Care Excellence (NICE)

 

(For practitioners dealing with Cannabis-based medicinal products in the UK).

Preview

 

Overview

 

This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy. 

 

In March 2021 NICE issued a clarification on recommendations for the use of unlicensed cannabis-based medicinal products for severe treatment-resistant epilepsy. This clarification has the same status as the guideline and should be read alongside it.

 

NICE has also published technology appraisal guidance on cannabidiol with clobazam for treating seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.

 

Products covered by the guideline include: 

    • cannabis-based products for medicinal use as set out by the UK Government in the 2018 Regulations

     

    • the licensed products delta-9-tetrahydrocannibinol combined with cannabidiol (Sativex) and nabilone

     

    • plant-derived cannabinoids such as pure cannabidiol (CBD)

     

    • synthetic compounds which are identical in structure to naturally occurring cannabinoids such as delta-9-tetrahydrocannabinol (THC), for example, dronabinol.